Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Metolazone

FDA-approved product (tablet, oral), marketed as Diulo, Metolazone, Mykrox and 1 more.

Registered studies
36
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Metolazone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Congestive heart failure
  • Heart failure
  • Hypertension
  • Preeclampsia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Sulfonamides, plain
FDA pharmacologic class
Thiazide-like Diuretic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA42.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli31.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

36registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Metolazone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Metolazone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure

    NCT00904488 · start 2008-10

    Registered record
    Registry ID
    NCT00904488
    Conditions
    Acute Decompensated Heart Failure
    Interventions
    Addition of oral Metolazone; Furosemide dose escalation
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2008-10
    Completion
    2017-11-14
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Decompensated Heart Failure
    InterventionAddition of oral Metolazone; Furosemide dose escalation
    PhasePhase 4
    Registry statusTerminated

  • A Comparison of Hydrochlorothiazide and Metolazone in Combination With Furosemide in Congestive Heart Failure Patients

    NCT00690521 · start 2004-10-26

    Registered record
    Registry ID
    NCT00690521
    Conditions
    Congestive Heart Failure
    Interventions
    Treatment of Furosemide + Hydrochlorothiazide; Treatment of Furosemide + Metolazone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2004-10-26
    Completion
    2009-11-10
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCongestive Heart Failure
    InterventionTreatment of Furosemide + Hydrochlorothiazide; Treatment of Furosemide + Metolazone
    PhaseNot applicable
    Registry statusCompleted

  • Fasting Study of Metolazone Tablets 10 mg and Zaroloxyn® Tablets 10 mg

    NCT00650195 · start 2004-02

    Registered record
    Registry ID
    NCT00650195
    Conditions
    Healthy
    Interventions
    Metolazone Tablets 10 mg; Zaroloxyn® Tablets 10 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2004-02
    Completion
    2004-03
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionMetolazone Tablets 10 mg; Zaroloxyn® Tablets 10 mg
    PhasePhase 1
    Registry statusCompleted

  • Fasting Study of Metolazone Tablets 5 mg and Zaroloxyn® Tablets 5 mg

    NCT00649181 · start 2003-10

    Registered record
    Registry ID
    NCT00649181
    Conditions
    Healthy
    Interventions
    Metolazone Tablets 5 mg; Zaroloxyn® Tablets 5 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2003-10
    Completion
    2003-11
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionMetolazone Tablets 5 mg; Zaroloxyn® Tablets 5 mg
    PhasePhase 1
    Registry statusCompleted

  • Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension

    NCT00684489 · start 2003-09

    Registered record
    Registry ID
    NCT00684489
    Conditions
    Hypertension
    Interventions
    clinical hypertension specialist-no specific med. Any anti-hypertension meds.; renin guided therapeutics-no specific med. Any anti-hypertensive med.
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-09
    Completion
    2005-09
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    Interventionclinical hypertension specialist-no specific med. Any anti-hypertension meds.; renin guided therapeutics-no specific med. Any anti-hypertensive med.
    PhaseNot applicable
    Registry statusCompleted

  • Fasting Study of Metolazone Tablets 2.5 mg and Zaroloxyn® Tablets 2.5 mg

    NCT00649051 · start 2002-12

    Registered record
    Registry ID
    NCT00649051
    Conditions
    Healthy
    Interventions
    Metolazone Tablets 2.5 mg; Zaroloxyn® Tablets 2.5 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2002-12
    Completion
    2003-01
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionMetolazone Tablets 2.5 mg; Zaroloxyn® Tablets 2.5 mg
    PhasePhase 1
    Registry statusCompleted